Delving into the Latest Updates on Cariprazine hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

cariprazine, Cariprazine hydrochloride (JAN/USAN), SYMVENU

+ [11]

Target

5-HT1A receptor x 5-HT2A receptor x D2 receptor x D3 receptor

Action

agonists, antagonists, partial agonists

Mechanism

5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor partial agonists(Dopamine D2 receptor partial agonists)

Therapeutic Areas

Nervous System DiseasesOther DiseasesCardiovascular Diseases+ [1]

Active Indication

Depressive Disorder, MajorBipolar and Related DisordersBipolar Disorder+ [7]

Inactive Indication

Bipolar II disorderChronic schizophreniaGeneralized anxiety disorder+ [2]

Originator Organization

Chemical Works of Gedeon Richter Plc

Active Organization

Gedeon Richter (UK) Ltd.

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Chemical Works of Gedeon Richter Plc

+ [5]

Inactive Organization

Forest Laboratories LLC

Tanabe Pharma Corp.Allergan Sales LLC

+ [1]

License Organization

Gedeon Richter (UK) Ltd.

Chemical Works of Gedeon Richter Plc

Hikma Pharmaceuticals Plc

+ [7]

Drug Highest PhaseApproved

First Approval Date

United States (17 Sep 2015),

Bipolar I disorderSchizophrenia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC21H33Cl3N4O

InChIKeyGPPJWWMREQHLQT-BHQIMSFRSA-N

CAS Registry1083076-69-0

Bipolar disorder is a common condition that can cause significant disability and risk for suicide. Second generation antipsychotic medications can be used to treat depression in bipolar disorder, yet we do not know how they work. Here, we will use a recently approved medication, cariprazine (Vraylar), to treat participants with bipolar depression. They will have brain imaging with PET scans before and during treatment to understand how the medication may be working. Particularly, we will look at the role of the D3 dopamine receptor.

Start Date06 Jan 2026

Sponsor / Collaborator

The New York State Psychiatric Institute

CTR20253439

/ RecruitingPhase 3

评价盐酸卡利拉嗪胶囊治疗精神分裂症急性发作期患者的有效性和安全性的多中心、随机、双盲双模拟、阳性药物平行对照Ⅲ期临床研究

[Translation] A multicenter, randomized, double-blind, double-dummy, positive drug parallel controlled phase III clinical study to evaluate the efficacy and safety of cariprazine hydrochloride capsules in the treatment of patients with acute exacerbation of schizophrenia

以阿立哌唑片为对照药，通过多中心、随机、双盲双模拟、平行对照设计的临床试验，评价盐酸卡利拉嗪胶囊治疗精神分裂症急性发作期患者的有效性和安全性

[Translation]

A multicenter, randomized, double-blind, double-dummy, parallel controlled clinical trial was conducted to evaluate the efficacy and safety of cariprazine hydrochloride capsules in the treatment of patients with acute exacerbation of schizophrenia, using aripiprazole tablets as the control drug.

Start Date22 Oct 2025

Sponsor / Collaborator

Jiangsu Nhwa Pharmaceutical Co., Ltd.

100 Clinical Results associated with Cariprazine hydrochloride

Login to view more data

100 Translational Medicine associated with Cariprazine hydrochloride

Login to view more data

100 Patents (Medical) associated with Cariprazine hydrochloride

Login to view more data

534

Literatures (Medical) associated with Cariprazine hydrochloride

01 Mar 2026·BIOMEDICAL CHROMATOGRAPHY

Development and Validation of a Novel and Cost‐Effective RP‐HPLC Method for the Separation of an Isomeric Impurity in Cariprazine Hydrochloride, an Antipsychotic Agent

Article

Author: Sanvatsarkar, Rakesh ; Ghosh, Brajadulal ; Korde, Ashok ; Birari, Dilip ; Shinde, Rajendra S.

ABSTRACT:

Cariprazine is an active pharmaceutical ingredient; it is indicated for the treatment of schizophrenia and depressive episodes associated with bipolar disorder. It is also employed in the management of treatment of major depressive disorder. A specific, novel, and reverse‐phase high‐performance liquid chromatography (RP‐HPLC) method was developed for the analysis of cis isomer (isomeric impurity) in cariprazine hydrochloride, and this method is validated as per ICH guideline. By reviewing online sources, it was noted that no literature is available related to the separation of cis isomer from the cariprazine hydrochloride drug molecule. RP‐HPLC method was developed using stationary phase as Intersil C8, 250 mm, 4.6 mm, 5 μm. Gradient elution was employed using mobile phase A, which consisted of a 0.05 M monobasic ammonium phosphate (NH 4 H 2 PO 4 ) buffer adjusted to pH 6.0 ± 0.05 with triethylamine; mobile phase B consisted of a homogeneous combination of acetonitrile and water (80:20, v/v). The chromatographic separation was performed at a flow rate of 1.2 mL/min, with the column oven temperature maintained at 35°C and the detection wavelength set at 215 nm. The total run time of this method is 20 min. The selected diluent was a mixture of acetonitrile, water, and 88% orthophosphoric acid in a volumetric ratio of 60:40 and 0.1 v/v/v. The developed method is robust, precise, accurate and linear in a series of LOQ to 500% level from the specification concentration limit. The newly developed RP‐HPLC method is applicable for the analysis of cis isomer in cariprazine hydrochloride samples.

01 Feb 2026·JOURNAL OF AFFECTIVE DISORDERS

Trajectories and predictors of depressive and anxiety symptom improvement with adjunctive cariprazine in antidepressant-treated adults with major depression: A Bayesian mega-analysis of two randomized trials

Article

Author: Strawn, Jeffrey R ; Mills, Jeffrey A

BACKGROUND:

Adjunctive cariprazine improves depressive symptoms in antidepressant-treated adults with major depressive disorder (MDD); however, how improvement in both anxiety and depressive symptoms varies across individuals and how to predict improvement with adjunctive cariprazine is unknown.

METHODS:

We conducted a mega-analysis of individual participant data (N = 1501) from two multicenter, double-blind, placebo-controlled phase 3 trials comparing adjunctive cariprazine 1.5 mg/day, 3 mg/day, and placebo in individuals receiving stable antidepressant treatment. The primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores; secondary outcomes included Clinical Global Impressions-Improvement (CGI-I) and Hamilton Anxiety Rating Scale (HAM-A) scores. Bayesian logarithmic trend models were used to characterize individual response trajectories and identify predictors of response.

RESULTS:

Adjunctive cariprazine produced greater improvement in depressive symptoms (vs. placebo) at both 1.5 mg/day (β = -0.319, p < 0.001) and 3 mg/day (β = -0.233, p = 0.002). Early improvement by week 2 predicted continued improvement across the 6-week trial. Greater baseline depression severity predicted a larger response (β = -0.075, p < 0.001), while more anxious patients had a smaller reduction in MADRS scores (β = 0.120, p < 0.001). Women (β = -0.190, p = 0.006) and those using SSRIs (β = -0.478, p < 0.001) also had greater improvement. For anxiety, higher baseline HAM-A scores predicted more improvement over time (β = -0.250, p < 0.001), while more severe baseline depression was associated with less anxiety improvement (β = 0.162, p < 0.001). Cariprazine 1.5 mg/day, but not 3 mg/day, modestly improved HAM-A scores relative to placebo (β = -0.147, p = 0.043).

CONCLUSIONS:

This mega-analysis highlights how variability in symptom trajectories with adjunctive cariprazine can be leveraged clinically to understand differences in response. These findings support using early symptom change and individual patient characteristics to inform clinical decision-making and tailor adjunctive treatment strategies.

21 Jan 2026·Central nervous system agents in medicinal chemistry

Clinical Effects of Recently Developed Antipsychotic Drugs in Schizophrenia

Article

Author: Coveñas, Rafael ; Werner, Felix-Martin

Introduction::

Schizophrenia and schizoaffective disorder are generally treated with second- generation antipsychotic drugs. These drugs are mostly dopaminergic (D2) and serotonergic (5-HT2A) antagonists. They sufficiently improve positive schizophrenia symptoms; however, they ameliorate negative symptoms and cognitive functions only to a limited extent.

Material and Methods::

We review novel antipsychotic drugs that exert partial agonism at dopaminergic and serotonergic receptors, such as cariprazine, brexpiprazole, and lumateperone. In addition, the mechanisms of action of non-dopaminergic antipsychotic drugs are described. Updated neural network models are used to explain the mechanisms of action of muscarinic (M4 and M1) receptor agonists (e.g., xanomeline combined with trospium) and trace-amine-associated receptor 1 (TAAR1) agonists (e.g., ulotaront). Phase 3 clinical trials of new third-generation antipsychotic drugs are also presented.

Results::

Novel antipsychotic drugs with partial agonism at D2 and D3 receptors improve positive and negative schizophrenia symptoms, as well as cognitive symptoms, more effectively than second- generation antipsychotic drugs. They are also well tolerated. M4 and M1 receptor agonists (i.e., xanomeline combined with trospium or emraclidine) and TAAR1 agonists (i.e., ulotaront) substantially improve negative schizophrenia symptoms and cognitive functions. These new nondopaminergic antipsychotic drugs better ameliorate negative symptoms and improve cognitive functions compared with second-generation antipsychotic drugs.

Discussion::

Results from phase 3 clinical studies indicate the clinical efficacy of new thirdgeneration antipsychotic drugs.

Conclusion::

Promising new antipsychotic drugs include cariprazine, brexpiprazole, lumateperone, ulotaront, and xanomeline combined with trospium. Phase 3 clinical studies have shown therapeutic effects superior to those achieved with second-generation antipsychotic drugs.

94

News (Medical) associated with Cariprazine hydrochloride

04 Feb 2026

·firstwordpharma.com

AbbVie touts 'record' sales amid uneven quarter for immunology stars

AbbVie beat sales forecasts by about $200 million in the fourth quarter as the company's fading blockbuster Humira outperformed expectations, while successor immunology drugs Rinvoq and Skyrizi posted uneven results. "We delivered record net sales and exceeded our financial commitments," stated CEO Rob Michael during the company's earnings call.The drugmaker reported quarterly revenue of $16.6 billion, up 10% year-over-year, topping analyst estimates of $16.4 billion. Sales for the full year reached $61.2 billion, a gain of 8.6%. Despite the beat, Leerink Partners analyst David Risinger suggested Humira was "contributing the vast majority of revenue upside," which may have worried investors and could explain why AbbVie shares were down roughly 4% on Wednesday.Quarterly sales in immunology, the company's biggest segment, were up 17.7% at $8.6 billion. Skyrizi climbed 32.5% to $5 billion, surpassing expectations of $4.9 billion, while Rinvoq rose 29.5% to $2.37 billion, but fell slightly short of forecasts.On the other hand, Humira — whose sales have been steadily declining since the introduction of biosimilar competition three years ago — brought in $1.2 billion, compared to the $1 billion analysts were expecting, though the drug's quarterly sales were still nearly 26% lower year-over-year.Still, Skyrizi and Rinvoq together delivered around $25.9 billion in combined sales for 2025, which is more than $8 billion year-over-year, "well exceeding our initial guidance expectations," said Chief Commercial Officer Jeff Stewart.He touted Skyrizi's continued growth trajectory specifically, noting the drug's total prescription share in the US biologics psoriasis market is now over 45% and accelerated in the fourth quarter. "Our in-play capture rates of new and switching patients has exceeded 55% across all lines of therapy, four times higher than the next closest competitor," he added.Meanwhile, the neuroscience segment also posted strong results, with revenue rising 17.9% to $3 billion. Antipsychotic Vraylar generated $1 billion in sales, up 10.5%, while therapeutic Botox grew 13.4% to $990 million. Double-digit gains were also posted by migraine therapies Ubrelvy ($339 million, +12%) and Qulipta ($288 million, +42.6%).Parkinson's treatment Vyalev, approved in late 2024, contributed $183 million in quarterly revenue, and $482 million for all of last year, but the company believes the therapy — a 24-hour continuous subcutaneous infusion of carbidopa and levodopa prodrugs — will hit blockbuster status in 2026. "The uptake is exceptionally strong across international markets, and we expect sales to ramp in the US, where [it] recently received full coverage," Stewart said.Revenues from the oncology portfolio were $1.7 billion in the quarter, a decrease of 1.5%, with Imbruvica down 20.8% to $671 million.Looking ahead, AbbVie forecasts approximately $67 billion in revenue for 2026, representing growth of about 9.5%, with adjusted earnings between $14.37 and $14.57 per share. Skyrizi and Rinvoq are expected to make up about $21.5 billion and $10.1 billion of that total, respectively.

Financial StatementDrug ApprovalClinical ResultBiosimilar

13 Jan 2026

·www.globenewswire.com

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Jan. 06, 2026 -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 44th Annual J.P. Morgan Healthcare Conference, to take place January 12-15, 2026, in San Francisco, California. Mapi is actively seeking new partnerships for its new proprietary Depot products. Company management will be available for one-on-one meetings during the J.P. Morgan Healthcare Conference to discuss potential joint development collaborations. Interested parties should contact Mapi directly. Mapi utilizes extended-release Depot technologies protected by strong IP to develop lifecycle Management products for innovative and existing commercially successful pharmaceuticals across multiple therapeutic areas. The Company currently has one partnered product covered under a commercialization agreement, GA Depot for Relapsing Forms of Multiple Sclerosis (RMS), and other products for diabetes and schizophrenia which are funded through Phase II results. The Company’s development pipeline also includes an injectable version of cariprazine, developed using Mapi’s Depot technology, which has demonstrated a long-acting release profile, for one monthly injection. It is designed to address an unmet need for patients with schizophrenia, bipolar I and major depression disorders. Mapi recently began enrolling patients in a Phase I/II study as described in ClinicalTrials.gov ID NCT07185815. Mapi is fully integrated in the development of Depot pharmaceuticals and offers partners multiple distinct technologies. The Company has an extensive R&D team with dedicated Depot labs, an experienced clinical team, as well as a large-scale, state-of-the-art GMP approved manufacturing facility for both clinical development and commercial supply. Mapi has the capabilities to efficiently develop Depot products by integrating R&D, clinical studies, registration and manufacturing and has a successful track record of improving time to market. Ehud Marom, Chairman and Chief Executive Officer, Mapi Pharma, said, “We have a number of compelling partnering opportunities in our current pipeline, including Deutetrabenazine (AUSTEDO® XR) Depot for the treatment of Huntington's disease and tardive dyskinesia, and Anastrazole (Arimidex®) Depot as an adjuvant treatment for postmenopausal women with hormone receptor-positive early breast cancer, as well as other candidates. We are seeking to apply our technologies to co-develop Depot drugs with companies that are interested in developing long-acting injectable lifecycle management products." Mapi Pharma (Mapi) is a clinical stage pharmaceutical company, engaged in development of high barrier-to-entry and high added-value life cycle management ("LCM") products and AB Rated Depot injectable products that target large markets that include complex active pharmaceutical ingredients ("APIs") and formulations. Mapi’s lead product is GA Depot which is partnered with Viatris (NASDAQ: VTRS) in an agreement under which Viatris was granted an exclusive license to commercialize the GA Depot injection product for Relapsing Forms of Multiple Sclerosis (RMS). Following successful Phase 3 results GA Depot is currently under FDA review. The Company is also marketing its own generic versions of Fingolimod (Gilenya®) and Apremilast (Otezla®) in specific geographic markets. Mapi's portfolio also includes a leading development of Depot drugs for Schizophrenia, GLP-1 for diabetes, weight loss, with innovative intellectual property. Mapi is built on strong chemical and pharmaceutical R&D and clinical development capabilities and a deep understanding of the global market and of regulatory needs. Mapi is a global company with an API production and aseptic Depot manufacturing and a Fill & Finish for injectable Finished Dosage Forms facilities. Mapi has strong IP positions, filing numerous patent applications for APIs and formulations. For more information, please visit www.mapi-pharma.com The content above comes from the network. if any infringement, please contact us to modify.

License out/in

01 Dec 2025

·www.globenewswire.com

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Management to Participate in 8th Annual Evercore Annual Healthcare ConferenceNESS ZIONA, Israel, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 8th Annual Evercore Annual Healthcare Conference, to take place December 2-4, 2025, in Miami, Florida. Mapi is actively seeking additional partnerships for its new proprietary Depot products. Company management will be available for one-on-one meetings during the Annual Evercore Annual Healthcare Conference to discuss potential joint development collaborations. Interested parties should contact Mapi directly or their representative at Evercore to arrange a meeting. Mapi utilizes extended-release Depot technologies with strong IP to develop Lifecycle Management products for innovative and existing commercially successful pharmaceuticals across multiple therapeutic areas. The Company currently has one product which is fully under a commercialization agreement, GA Depot for Relapsing Forms of Multiple Sclerosis (RMS) and other products for diabetes and schizophrenia which are funded through Phase II results. The development pipeline also includes an injectable version of cariprazine, developed using Mapi’s Depot technology, which has demonstrated a long-acting release profile, for one monthly injection. It is designed to address an unmet need in the treatment of schizophrenia, bipolar I and major depression disorders. Mapi recently began enrolling patients in a Phase I/II study. Mapi is fully integrated in the development of Depot pharmaceuticals and offers partners multiple distinct technologies. The Company has an extensive R&D team with dedicated Depot labs, experienced clinical team, as well as a large-scale, state-of-the-art GMP approved manufacturing facility for both clinical development and commercial supply. Mapi has the capabilities to efficiently develop Depot products by integrating R&D, clinical studies, registration and manufacturing with a successful track record of improving time to market. Ehud Marom, Chairman and Chief Executive Officer, Mapi Pharma, said, “We have a number of compelling partnering opportunities in our current pipeline, including Deutetrabenazine (AUSTEDO® XR) Depot for the treatment of Huntington's disease and tardive dyskinesia, and Anastrazole (Arimidex®) Depot as an adjuvant treatment for postmenopausal women with hormone receptor-positive early breast cancer as well as other candidates. We can also apply our technologies to co-develop Depot drugs with companies that are interested in developing long-acting injectable lifecycle management versions of their molecules." About Mapi PharmaMapi Pharma (Mapi) is a clinical stage pharmaceutical company, engaged in development of high barrier-to-entry and high added-value life cycle management ("LCM") products and AB Rated Depot injectable products that target large markets that include complex active pharmaceutical ingredients ("APIs") and formulations. Mapi’s lead product is GA Depot which is partnered with Viatris (NASDAQ: VTRS) in an agreement under which Viatris was granted an exclusive license to commercialize the GA Depot injection product for Relapsing Forms of Multiple Sclerosis (RMS). Following successful Phase 3 results GA Depot is currently under FDA review. The Company is also marketing its own generic versions of Fingolimod (Gilenya®) and Apremilast (Otezla®) in specific geographic markets. Mapi's portfolio also includes a leading development of Depot drugs for Schizophrenia, GLP-1 for diabetes, weight loss, with innovative intellectual property. Mapi is built on strong chemical and pharmaceutical R&D and clinical development capabilities and a deep understanding of the global market and of regulatory needs. Mapi is a global company with an API production and aseptic Depot manufacturing and a Fill & Finish for injectable Finished Dosage Forms facilities. Mapi has strong IP positions, filing numerous patent applications for APIs and formulations. For more information, please visit www.mapi-pharma.com Contacts:Alex MogleVice President, Corporate DevelopmentMapi Pharma+972 52 6080297alex@mapi-pharma.com Brian RitchieManaging DirectorLifeSci Advisors, LLCbritchie@lifesciadvisors.com

License out/inPhase 2Phase 3

100 Deals associated with Cariprazine hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09876	Cariprazine hydrochloride	N05AX15	DB06016

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder, Major	United States	AbbVie, Inc.	16 Dec 2022
Bipolar and Related Disorders	Canada	Gedeon Richter (UK) Ltd.	27 Apr 2022
Bipolar Disorder	Canada	Allergan, Inc.	22 Apr 2022
Bipolar I disorder	United States	AbbVie, Inc.	17 Sep 2015
Schizophrenia	United States	AbbVie, Inc.	17 Sep 2015

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart Septal Defects, Atrial	Phase 3	United States	AbbVie, Inc.	07 Jul 2022
Irritable Mood	Phase 3	United States	AbbVie, Inc.	07 Jul 2022
Acute schizophrenia	Phase 3	South Korea	Whan In Pharmaceutical Co., Ltd.	19 Nov 2021
Autism Spectrum Disorder	Phase 3	United States	AbbVie, Inc.	01 Feb 2021
Depressive Disorder	Phase 3	Bulgaria	Forest Laboratories LLC	17 Mar 2016
Depressive Disorder	Phase 3	Estonia	Forest Laboratories LLC	17 Mar 2016
Depressive Disorder	Phase 3	Lithuania	Forest Laboratories LLC	17 Mar 2016
Depressive Disorder	Phase 3	Poland	Forest Laboratories LLC	17 Mar 2016
Chronic schizophrenia	Phase 3	Japan	Tanabe Pharma Corp.	01 May 2012
Mania	Phase 3	United States	Forest Laboratories LLC	01 Feb 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NEWS Manual	Not Applicable	Schizophrenia	116	cariprazine (women outpatients)	extzahlumn(gsgqhyodbw) = There was a significant change from baseline in women to week 16 in the SAND scores: negative symptoms decreased by 6.2, positive symptoms decreased with 1.0, which is a remarkable, combined 7.2 drop. sssvdwgzpe (mgnzhqkooc )	Positive	18 Oct 2023
NCT03573297 (CTgov)	Phase 3	Mania \| Depressive Disorder \| Bipolar I disorder	901	placebo (Double-Blind Placebo QD)	bvjzdoqsdz(iwwqjkkncb) = kpxeezxpio hdmvrmbeyw (fjeyvnuqmh, wrspbpbbvi - liqxjliwxg) View more	-	28 Sep 2023
				Cariprazine (Double-Blind Cariprazine 1.5 mg QD)	bvjzdoqsdz(iwwqjkkncb) = fewxtmcdsy hdmvrmbeyw (fjeyvnuqmh, gkesfypdzg - zcvfwgqlul) View more
NCT03738215 (Pubmed \| Am J Psychiatry)	Phase 3	Depressive Disorder, Major	751	Placebo	ogfpruxiur(iiqnmiekxn) = vejiximqyn huilkschwe (ilbxpbirqw )	Positive	15 Feb 2023
				Cariprazine 1.5 mg/day	ogfpruxiur(iiqnmiekxn) = hjxqbmkqla huilkschwe (ilbxpbirqw )
NCT03738215 (CTgov)	Phase 3	Depressive Disorder, Major	759	Placebo (Placebo + ADT)	sowlabpelf(vhbnnviegx) = hrbgxiawnr duiiayenjs (kblkenqukp, 0.70) View more	-	25 Oct 2022
				Cariprazine (Cariprazine 1.5 mg/Day + ADT)	sowlabpelf(vhbnnviegx) = zzcwqmtush duiiayenjs (kblkenqukp, 0.70) View more
NCT03739203 (CTgov)	Phase 3	Depressive Disorder, Major	752	Placebo (Placebo + ADT)	rxpwtlzalh(dqsewqnuwe) = rmtaqeuytm xbxvsdbucy (fvvrrbcsif, 0.70) View more	-	21 Sep 2022
				ADT+Cariprazine (Cariprazine 1.5 mg/Day + ADT)	rxpwtlzalh(dqsewqnuwe) = oczgoquejo xbxvsdbucy (fvvrrbcsif, 0.69) View more
NCT03593213 (CTgov)	Phase 3	Schizophrenia	587	Placebo (Placebo (Double-blind Treatment Period))	oesynqpcaw(mwwjcuxogu) = vkfrriwjbj uyfqkaifxf (bcgcawjvkn, zsicsiydiw - kgeueiutbt) View more	-	08 Mar 2022
				Cariprazine (Cariprazine 3.0 mg/Day (Double-blind Treatment Period))	oesynqpcaw(mwwjcuxogu) = bgakupfyle uyfqkaifxf (bcgcawjvkn, zotrzbaxxt - gohxksqdty) View more
NCT01626885 (CTgov)	Phase 2/3	Schizophrenia	42	MP-214	ayixgxizgp = hywxmkhofc awjdziwhof (zjkwxkgwxk, titpgnbzsw - dvjtqmgcdz) View more	-	13 Apr 2021
NCT01625897 (CTgov)	Phase 2/3	Chronic schizophrenia \| Schizophrenia	125	MP-214 (MP-214 1.5-9mg)	bkihapjikm = mficinjeva kbudwtdxft (jsdsamntxh, xtvlqwzwzx - khapysovkp) View more	-	13 Apr 2021
				risperidone (Risperidone 2-12mg)	bkihapjikm = msqequdztp kbudwtdxft (jsdsamntxh, tjgssuaffd - hehldlwyhe) View more
NCT01626872 (CTgov)	Phase 2/3	Schizophrenia	254	MP-214 3mg (MP-214 3mg)	jauihknlll = bxixdssvie ktpzfftyxc (hqtepyxgso, wxegihllca - bihwialvwa) View more	-	12 Apr 2021
				MP-214 6mg (MP-214 6mg)	jauihknlll = orgtvtllby ktpzfftyxc (hqtepyxgso, dfrnwgpgxo - jvcywwjzwx) View more
NCT00862992 (CTgov)	Phase 2	Schizophrenia	34	Cariprazine (Cariprazine 3 mg)	htzzymtyhm = iaxanthkfj lokmqfenoj (rfeiczhoeh, tngwcvlhyv - xuelbzcoma) View more	-	12 Apr 2021
				Cariprazine (Cariprazine 6 mg)	htzzymtyhm = norpsxqwxj lokmqfenoj (rfeiczhoeh, gfolqnaitg - uantitgqkp) View more